Drug Profile
Research programme: autosomal dominant polycystic kidney disease therapeutics - Endocyte
Alternative Names: EC-0371; FC-RapaLatest Information Update: 31 Dec 2018
Price :
$50
*
At a glance
- Originator Endocyte
- Class Drug conjugates; Macrolides; Small molecules
- Mechanism of Action MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autosomal dominant polycystic kidney disease
Most Recent Events
- 21 Dec 2018 Endocyte has been acquired by Novartis
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autosomal-dominant-polycystic-kidney-disease in USA
- 03 Aug 2012 Preclinical trials in Autosomal dominant polycystic kidney disease in USA (unspecified route)